[Treatment of clinically localized prostate cancer. Part I--observation or treatment?].
The optimal management of clinically localized (T1, T2) prostate cancer remains controversial. In response to these controversies the American Urological Association guidelines considered surgery, radiotherapy or watchful waiting to be options, because the literature does not provide clear evidence for the superiority of any one treatment. The aim of this paper is presentation of current knowledge regarding this problem.
Szelachowska
Jolanta
J
Medical University of Wroclaw, Poland.
Kornafel
Jan
J
Gisterek
Iwona
I
D000368:Aged; D000369:Aged, 80 and over; D002277:Carcinoma / Q000097:blood / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D002986:Clinical Trials as Topic; D019317:Evidence-Based Medicine; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D019370:Observation; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy / Q000379:methods; D011470:Prostatic Hyperplasia / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D011788:Quality of Life; D016019:Survival Analysis
D006728:Hormones; D017430:Prostate-Specific Antigen